• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制剂与疟原虫和人类的SAHH结合模式的结构洞察:姜黄素与抗疟药物靶点的相互作用

Structural insight into binding mode of inhibitor with SAHH of and human: interaction of curcumin with anti-malarial drug targets.

作者信息

Singh Dev Bukhsh, Dwivedi Seema

机构信息

Department of Biotechnology, Institute of Biosciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur, 208024 India ; School of Biotechnology, Gautam Buddha University, Gautam Budh Nagar, 201308 India.

School of Biotechnology, Gautam Buddha University, Gautam Budh Nagar, 201308 India.

出版信息

J Chem Biol. 2016 Aug 15;9(4):107-120. doi: 10.1007/s12154-016-0155-7. eCollection 2016 Oct.

DOI:10.1007/s12154-016-0155-7
PMID:27698948
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5026646/
Abstract

S-adenosyl-L-homocysteine hydrolase of (PfSAHH) is a potential drug target against malaria, and selective inhibition of PfSAHH is the excellent strategy to prevent the growth of parasite inside the host. Therefore, a comparative analysis of human S-adenosyl-L-homocysteine hydrolase (HsSAHH) and PfSAHH has been performed to explore the structural differences. Structural superimposition of PfSAHH and HsSAHH has generated the RMSD of 0.749 Å over 394 alpha carbon pairs. Residues of PfSAHH from position Tyr152 to Lys193 aligned with insertion/deletion region in HsSAHH, and these extra residues results in an extent of variation in cavity region of PfSAHH. Nicotinamide adenine dinucleotide (NAD) was observed to form hydrogen bonding with Thr201, Thr202, Thr203, Asn235, Val268, Glu287, Asn322, Ile343, Asn391, Lys473, and Tyr477 and also forms hydrophobic interactions with Val268, Ile288, and Thr320 of PfSAHH. In comparison to HsSAHH, Asn322, Lys473, and Tyr477 residues of PfSAHH are unique in interaction with NAD. 2-Fluoroaristeromycin and other analogues of aristeromycin have shown the good binding affinity for both enzymes. Structural differences between PfSAHH and HsSAHH might be employed to design the potential inhibitor of PfSAHH. To find the target enzyme responsible for an anti-malarial effect, molecular docking and interaction analysis of curcumin were performed with 34 drug targets of . Curcumin shows high affinity for binding with HGPRT of PfHGPRT, and an anti-malarial effect of curcumin might be due to binding with PfHGPRT.

摘要

疟原虫的S-腺苷-L-高半胱氨酸水解酶(PfSAHH)是抗疟疾的一个潜在药物靶点,选择性抑制PfSAHH是阻止寄生虫在宿主体内生长的极佳策略。因此,已对人S-腺苷-L-高半胱氨酸水解酶(HsSAHH)和PfSAHH进行了比较分析以探究结构差异。PfSAHH和HsSAHH的结构叠加在394个α碳对上产生了0.749 Å的均方根偏差(RMSD)。PfSAHH中从Tyr152到Lys193位置的残基与HsSAHH中的插入/缺失区域对齐,这些额外的残基导致PfSAHH腔区域出现一定程度的变化。观察到烟酰胺腺嘌呤二核苷酸(NAD)与PfSAHH的Thr201、Thr202、Thr203、Asn235、Val268、Glu287、Asn322、Ile343、Asn391、Lys473和Tyr477形成氢键,并且还与PfSAHH的Val268、Ile288和Thr32o形成疏水相互作用。与HsSAHH相比,PfSAHH的Asn322、Lys473和Tyr477残基在与NAD的相互作用方面是独特的。2-氟阿糖腺苷和阿糖腺苷的其他类似物对这两种酶均显示出良好的结合亲和力。PfSAHH和HsSAHH之间的结构差异可用于设计PfSAHH的潜在抑制剂。为了找到负责抗疟作用的靶酶,对姜黄素与疟原虫的34个药物靶点进行了分子对接和相互作用分析。姜黄素显示出与PfHGPRT的次黄嘌呤-鸟嘌呤磷酸核糖转移酶(HGPRT)结合的高亲和力,姜黄素的抗疟作用可能归因于与PfHGPRT的结合。

相似文献

1
Structural insight into binding mode of inhibitor with SAHH of and human: interaction of curcumin with anti-malarial drug targets.抑制剂与疟原虫和人类的SAHH结合模式的结构洞察:姜黄素与抗疟药物靶点的相互作用
J Chem Biol. 2016 Aug 15;9(4):107-120. doi: 10.1007/s12154-016-0155-7. eCollection 2016 Oct.
2
Docking and in silico ADMET studies of noraristeromycin, curcumin and its derivatives with Plasmodium falciparum SAH hydrolase: a molecular drug target against malaria.与疟原虫 SAH 水解酶对接和计算机 ADMET 研究:抗疟疾的分子药物靶点。
Interdiscip Sci. 2013 Mar;5(1):1-12. doi: 10.1007/s12539-013-0147-z. Epub 2013 Apr 19.
3
Crystal structure of S-adenosyl-L-homocysteine hydrolase from the human malaria parasite Plasmodium falciparum.来自人类疟原虫恶性疟原虫的S-腺苷-L-高半胱氨酸水解酶的晶体结构。
J Mol Biol. 2004 Oct 29;343(4):1007-17. doi: 10.1016/j.jmb.2004.08.104.
4
Structure, evolution, and inhibitor interaction of S-adenosyl-L-homocysteine hydrolase from Plasmodium falciparum.恶性疟原虫S-腺苷-L-高半胱氨酸水解酶的结构、进化及抑制剂相互作用
Proteins. 2003 Sep 1;52(4):624-32. doi: 10.1002/prot.10446.
5
[Structural biology for developing antimalarial compounds].[用于开发抗疟化合物的结构生物学]
Yakugaku Zasshi. 2013;133(5):527-37. doi: 10.1248/yakushi.13-00001-3.
6
Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.2-修饰阿瑞霉素及其类似物的合成作为恶性疟原虫S-腺苷-L-高半胱氨酸水解酶的有效抑制剂
Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. doi: 10.1016/j.bmc.2008.01.046. Epub 2008 Jan 30.
7
Three-dimensional structure of S-adenosyl-L-homocysteine hydrolase from Plasmodium falciparum.
Nucleic Acids Symp Ser (Oxf). 2004(48):281-2. doi: 10.1093/nass/48.1.281.
8
Crystallization and preliminary X-ray crystallographic analysis of Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
Protein Pept Lett. 2004 Apr;11(2):201-5. doi: 10.2174/0929866043478248.
9
[S-adenosyl-L-homocysteine hydrolase as an attractive target for antimicrobial drugs].[作为抗菌药物诱人靶点的S-腺苷-L-高半胱氨酸水解酶]
Yakugaku Zasshi. 2007 Jun;127(6):977-82. doi: 10.1248/yakushi.127.977.
10
Purification and properties of recombinant Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.重组恶性疟原虫S-腺苷-L-高半胱氨酸水解酶的纯化及特性
J Biochem. 2001 Jan;129(1):101-5. doi: 10.1093/oxfordjournals.jbchem.a002819.

引用本文的文献

1
Curcumin and Its Derivatives as Potential Antimalarial and Anti-Inflammatory Agents: A Review on Structure-Activity Relationship and Mechanism of Action.姜黄素及其衍生物作为潜在的抗疟和抗炎剂:结构-活性关系及作用机制综述
Pharmaceuticals (Basel). 2023 Apr 18;16(4):609. doi: 10.3390/ph16040609.
2
The Potential use of a Curcumin-Piperine Combination as an Antimalarial Agent: A Systematic Review.姜黄素-胡椒碱组合作为抗疟剂的潜在用途:一项系统评价
J Trop Med. 2021 Oct 11;2021:9135617. doi: 10.1155/2021/9135617. eCollection 2021.

本文引用的文献

1
A novel inhibitor of Plasmodium falciparum spermidine synthase: a twist in the tail.一种新型恶性疟原虫亚精胺合成酶抑制剂:尾部的转折
Malar J. 2015 Feb 5;14:54. doi: 10.1186/s12936-015-0572-z.
2
Drawing the PDB: Protein-Ligand Complexes in Two Dimensions.绘制PDB:二维蛋白质-配体复合物
ACS Med Chem Lett. 2010 Aug 31;1(9):540-5. doi: 10.1021/ml100164p. eCollection 2010 Dec 9.
3
Molecular characterization of Plasmodium falciparum uracil-DNA glycosylase and its potential as a new anti-malarial drug target.恶性疟原虫尿嘧啶-DNA糖基化酶的分子特征及其作为新型抗疟药物靶点的潜力
Malar J. 2014 Apr 17;13:149. doi: 10.1186/1475-2875-13-149.
4
[Structural biology for developing antimalarial compounds].[用于开发抗疟化合物的结构生物学]
Yakugaku Zasshi. 2013;133(5):527-37. doi: 10.1248/yakushi.13-00001-3.
5
Docking and in silico ADMET studies of noraristeromycin, curcumin and its derivatives with Plasmodium falciparum SAH hydrolase: a molecular drug target against malaria.与疟原虫 SAH 水解酶对接和计算机 ADMET 研究:抗疟疾的分子药物靶点。
Interdiscip Sci. 2013 Mar;5(1):1-12. doi: 10.1007/s12539-013-0147-z. Epub 2013 Apr 19.
6
admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.ADMETSAR:一个全面的化学 ADMET 性质评估资源和免费工具。
J Chem Inf Model. 2012 Nov 26;52(11):3099-105. doi: 10.1021/ci300367a. Epub 2012 Nov 1.
7
Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions.全植物提取物与单一化合物治疗疟疾:协同作用和积极相互作用。
Malar J. 2011 Mar 15;10 Suppl 1(Suppl 1):S4. doi: 10.1186/1475-2875-10-S1-S4.
8
The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria.植物免疫调节剂姜黄素有望成为治疗脑型疟疾的辅助疗法。
Malar J. 2011 Mar 15;10 Suppl 1(Suppl 1):S10. doi: 10.1186/1475-2875-10-S1-S10.
9
[Synthesis and antiviral evaluation against Vaccinia virus of new N¹-oxide analogues of 5'-noraristeromycin].[新型5'-去甲司他霉素N¹-氧化物类似物的合成及其对痘苗病毒的抗病毒活性评价]
Bioorg Khim. 2010 Nov-Dec;36(6):797-801.
10
Toward the estimation of the absolute quality of individual protein structure models.朝着估计个体蛋白质结构模型的绝对质量的方向努力。
Bioinformatics. 2011 Feb 1;27(3):343-50. doi: 10.1093/bioinformatics/btq662. Epub 2010 Dec 5.